<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02298777</url>
  </required_header>
  <id_info>
    <org_study_id>5723</org_study_id>
    <nct_id>NCT02298777</nct_id>
  </id_info>
  <brief_title>Metabolomic Analysis of Systemic Sclerosis</brief_title>
  <acronym>SCLEROMICS</acronym>
  <official_title>Metabolomic Analysis of Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently investigators do not have diagnostic and prognostic markers for SSc which almost
      always starts with a vascular disease (Raynaud's disease) isolated for several years.

      The primary purpose is to highlight discriminating metabolic profiles depending on the
      characteristics of the disease, allowing early diagnosis of SSc at the onset of vascular
      lesions, by comparing the profiles of SSc beginners (&lt;3 years) to established forms (&gt; 3
      years).

      Secondary purposes:

        -  Prognosis: to study the metabolomics profile of SSc when a visceral complication occurs

        -  Diagnosis: to compare the metabolomics profile of SSc to undifferentiated connective
           tissue disease (UCDT), Raynaud's disease (RD), vascular disease (VD) and healthy
           controls

        -  Exploratory: to compare the metabolomics profile of blood, urine and skin of SSc
           patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change of metabolomics profiles between SSc beginners (&lt;3 years) and SSc established forms (&gt; 3 years) at baseline inclusion.</measure>
    <time_frame>1 point at patient's inclusion visit</time_frame>
    <description>Metabolomic profiles will be classified in a database and compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study and comparison of discriminating metabolomics profiles for prognosis, diagnosis and exploration of SSc.</measure>
    <time_frame>1st point at patient's inclusion visit (all arms) + 2nd point at patient's complication (group1) during 3 years</time_frame>
    <description>Metabolomic profiles will be classified in a database and compared between each other's (SSc, UCDT, RD, VD and healthy control arms) We will look for a correlation between these profiles and the evolution of clinical and biological characteristics of SSc (SSc arm)</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Scleroderma (Limited and Diffuse)</condition>
  <condition>Undifferentiated Connective Tissue Disease</condition>
  <condition>Raynaud Disease</condition>
  <condition>Vascular Disease</condition>
  <condition>Healthy Control Subjects</condition>
  <arm_group>
    <arm_group_label>Scleroderma (SSc) patients (beginners and established forms).</arm_group_label>
    <description>Patients with the ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001)
Biological samples (skin, urine and blood):
1st point at patient's inclusion visit
2nd point (optional) at SSc patient's visceral complication (assessed during 3 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Undifferentiated Connective Tissue Disease (UCDT) patients</arm_group_label>
    <description>Patients with criteria proposed by Mosca et al. (1998)
Biological samples (skin, urine and blood):
- 1single point at patient's inclusion visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Raynaud disease patients</arm_group_label>
    <description>Patients with primary and isolated Raynaud disease
Biological samples (skin, urine and blood):
- 1single point at patient's inclusion visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vascular disease patients</arm_group_label>
    <description>Patients with vascular disease (type 2 diabetes, occlusive vascular disease, history of myocardial infarction or ischemic stroke)
Biological samples (skin, urine and blood):
- 1single point at patient's inclusion visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control subjects</arm_group_label>
    <description>Healthy subjects (no sign of connective tissue disease, no Raynaud, no vascular disease)
Biological samples (skin, urine and blood):
- 1single point at patient's inclusion visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>- Skin biopsy - Urine sample - Blood sample</intervention_name>
    <arm_group_label>Scleroderma (SSc) patients (beginners and established forms).</arm_group_label>
    <arm_group_label>Undifferentiated Connective Tissue Disease (UCDT) patients</arm_group_label>
    <arm_group_label>Raynaud disease patients</arm_group_label>
    <arm_group_label>Vascular disease patients</arm_group_label>
    <arm_group_label>Healthy control subjects</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with systemic sclerosis (SSc),
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Group 1 (scleroderma) : Patients with ACR / EULAR (2012) and / or criteria of Leroy
             and Medsger (2001)

          -  Group 2 (UCDT) : Patients with criteria proposed by Mosca et al. (1998)

          -  Group 3 (Raynaud) : Patients with primary and isolated Raynaud disease

          -  Group 4 (vascular disease) : Patients with type 2 diabetes, occlusive vascular
             disease, history of myocardial infarction or ischemic stroke

          -  Group 5 (healthy control) : healthy subjects (no sign of connective tissue disease, no
             Raynaud, no vascular disease)

        Exclusion criteria:

          -  Group 1 (scleroderma) : Patients not fulfilling ACR / EULAR (2012) and / or criteria
             of Leroy and Medsger (2001), or with another auto-immune disease

          -  Group 2 (UCDT) : Patients not fulfilling criteria proposed by Mosca et al. (1998)

          -  Group 3 (Raynaud) : Patients with no Raynaud disease

          -  Group 4 (vascular disease) : Patients with no vascular disease

          -  Group 5 (healthy control) : Patients with sign of connective tissue disease, Raynaud,
             or vascular disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chatelus Emmanuel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chatelus Emmanuel, MD</last_name>
    <phone>03 88 12 81 15</phone>
    <phone_ext>0033</phone_ext>
    <email>emmanuel.chatelus@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kleinmann Jean-François</last_name>
    <phone>03 88 12 79 62</phone>
    <email>jean-francois.kleinmann@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BONNOTTE Bernard</last_name>
      <email>bernard.bonnote@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SALMON Jean-Hughes, MD</last_name>
      <email>jhsalmon@chu-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2014</study_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
    <mesh_term>Raynaud Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

